Aura Biosciences (AURA) CEO sale covers RSU tax obligations

Rhea-AI Filing Summary

Aura Biosciences, Inc. director and President & Chief Executive Officer Elisabet de los Pinos reported an automatic sale of common stock to cover taxes on vesting restricted stock units. On January 20, 2026, she sold 16,928 shares of common stock at a weighted average price of $4.86 per share in multiple trades within a price range of $4.73 to $4.86. After this transaction, she beneficially owned 457,463 shares of Aura Biosciences common stock directly. An additional 127,763 shares were reported as indirectly owned through the Elisabet de los Pinos Revocable Trust, of which she is a trustee. The filing notes that the sales were solely to satisfy tax withholding obligations and were not made at her discretion.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

de los Pinos Elisabet

(Last) (First) (Middle)

C/O AURA BIOSCIENCES, INC.

80 GUEST STREET

(Street)

BOSTON MA 02135

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		S(1)		16,928	D	$4.86(2)	457,463	D
Common Stock								127,763	I	By EdIP Revocable Trust(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.73 to $4.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The shares are held by the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which the Reporting Person is a trustee.

Remarks:

President and Chief Executive Officer

	/s/ Conor Kilroy, as Attorney-in-Fact	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did AURA report in this Form 4?

The Form 4 reports that Elisabet de los Pinos, a director and the President & Chief Executive Officer of Aura Biosciences, Inc. (AURA), sold 16,928 shares of common stock on January 20, 2026.

At what price were the Aura Biosciences (AURA) shares sold by the CEO?

The 16,928 shares of Aura Biosciences common stock were sold at a weighted average price of $4.86 per share, in multiple transactions at prices ranging from $4.73 to $4.86.

Why did the Aura Biosciences CEO sell shares according to the Form 4?

The filing states that the reported sales represent shares sold to cover tax withholding obligations related to the vesting of restricted stock units and that these sales were automatic and not at the CEO's discretion.

How many Aura Biosciences (AURA) shares does the CEO own after the reported sale?

Following the reported transaction, Elisabet de los Pinos beneficially owned 457,463 shares of Aura Biosciences common stock directly, plus 127,763 shares indirectly through the Elisabet de los Pinos Revocable Trust.

What is the nature of the indirect ownership reported for AURA shares?

The Form 4 reports 127,763 shares of Aura Biosciences common stock as indirectly owned through the Elisabet de los Pinos Revocable Trust, dated April 8, 2016, where Elisabet de los Pinos is a trustee.

Does this Aura Biosciences Form 4 mention a Rule 10b5-1 trading plan?

The document includes a standard checkbox regarding transactions under a Rule 10b5-1(c) plan, but the detailed explanation specifies that the sales were to cover tax withholding on restricted stock unit vesting and were automatic.